Search results

Filters
Close
ADDED DATE
Added date
AUTHOR Please select
TOPICS Please select
WATCH / LISTEN / READ TIME
ACC.24: Restrictive Vs Liberal Blood Transfusion in MI Patients: MINT
Author(s): Andrew P DeFillipis Added: 1 week ago
ACC.24 — Dr Andrew P DeFilipis (Vanderbilt University Medical Center, US) joins us onsite at ACC to discuss the findings from a subgroup analysis of the MINT Trial (NCT02981407).MINT is a randomised parallel assignment trial which aims to compare liberal and restrictive blood cell transfusion strategies in patients who have had an acute myocardial infarction (AMI) and are anaemic. Findings were… View more

Heart Failure

MI/ACS
Author(s): Antonio Gutierrez , Sunil V Rao Added: 3 years ago
Current evidence-based therapies for ischemic heart disease include antithrombotic and antiplatelet medications that reduce the risk for ischemic outcomes such as myocardial infarction and stroke.1 Given their mechanism of action, bleeding is a risk with these agents, especially when combined with invasive procedures.2 In addition to overt bleeding, clinical trials of antithrombotic strategies… View more

Prevention & Chronic Conditions
Author(s): Brian A Bruckner , Matthias Loebe Added: 3 years ago
To view the full article in PDF format, please click on the icon above. View more

Vascular Disease and Surgery
Jeffrey L Carson
Dr Jeffrey Carson, currently serving as the Provost, New Brunswick at Rutgers Biomedical and Health Sciences, brings a wealth of experience and leadership to the field of medicine. Formerly the Chief of the Division of General Internal Medicine until 2015, he holds the esteemed position of Distinguished Professor of Medicine and occupies the Richard C. Reynolds, M.D. Chair in General Internal… View more
AHA 2023 Late-Breaking Science Lineup Revealed
Added: 6 months ago Source:  AHA, Jordan Rance
The American Heart Association has announced eight late-breaking science sessions to be presented in Philadelphia from November 10th to November 13th. AHA is focussed on innovation in cardiovascular disease for scientists, clinicians, researchers and other healthcare professionals. Among the event’s highlights are eight late-breaking trial sessions, as listed below. Watch our coverage of… View more
Author(s): Howard C Herrmann Added: 3 years ago
Mitral regurgitation (MR) is most often caused by degenerative disease of the leaflets or develops functionally as a consequence of left ventricular disease (see Figure 1). Patients with severe MR have dyspnea on exertion, fatigue, and, when associated with left ventricular dysfunction or pulmonary hypertension, reduced survival.1 Therefore, surgery to repair or replace the mitral valve is… View more

Vascular Disease and Surgery

Intervention
Author(s): Steven V Manoukian , Michele D Voeltz , Frederick Feit Added: 3 years ago
Non-ST-segment elevation (NSTE) acute coronary syndromes (ACS) include unstable angina (UA) and NSTE myocardial infarction (NSTEMI), and account for 1.5 million hospitalizations in the US annually.1 Patients with ACS are typically managed by initial medical stabilization followed by an early invasive approach, whereby cardiac catheterization is performed, usually within 24 hours of admission… View more

MI/ACS
Author(s): David E Allie , Chris J Herbert , Craig M Walker Added: 3 years ago
Despite the recent introduction of vascular closure device (VCD) technology, vascular access site complications remain the leading source of morbidity and costs after the approximately eight/eight and a half million percutaneous catheter-based procedures performed annually worldwide. VCD trials consistently demonstrate increased patient satisfaction, early ambulation, and decreased hospital… View more

Imaging & Diagnostics
Author(s): Brian Pearlman , Taffere Mihretu Added: 3 years ago
Congestive heart failure (CHF) is a rapidly growing public health problem, affecting nearly five million people in the US alone, with nearly half a million new cases annually.The prevalence of CHF is highest in the elderly; ten out of every 1,000 persons over age 65 are affected. Anemia has been considered a modifiable comorbidity in heart failure. Utilizing the World Health Organization (WHO)… View more

Heart Failure
Shockwave and Non-transfemoral Transcatheter Aortic Valve Replacement
Author(s): Eden C Payabyab , Lindsay S Elbaum , Navneet Sharma , et al Added: 2 years ago

Vascular Disease and Surgery